In Brief: Boston Scientific breather
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific breather: Firm ends shopping spree and plans to "take a breath for a little while" on the merger and acquisition front, company Chairman and CEO Pete Nicholas tells investors at the Piper Jaffray medical device conference. The minimally invasive devices firm has entered seven merger agreements since August 1994, making deals for: Cardiovascular Imaging Systems, Scimed, Heart Technology, EP Technologies, Meadox Medical, Vesica Medical, and Symbiosis...
You may also be interested in...
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.